



**Comorbidity and Polypharmacy among People Living with HIV in the
United States Stratified by Age, Sex, and Race: Updated Evidence
from a Contemporary Cohort**

Supplemental Material


Supplemental Figure 1. Study Design



Supplemental Figure 2. Identification and attrition of (A) People living with HIV cohort and (B) People without HIV cohort



B



Abbreviations: ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; PEP, post exposure prophylaxis; PrEP, pre-exposure prophylaxis.

^a HIV/AIDS diagnosis code during the 5 years prior to index date and/or 30 days post index date that did not coincide with an HIV antibody screening test.

^b Individuals with a pharmacy claim for an NRTI or medical claim for cabotegravir at any time in the 5 years prior to index or 30 days post index were eligible for inclusion, while those with pharmacy claims for any other ART were excluded.

Supplemental Table 1. List of Comorbid Conditions

Category	Conditions
Cardiovascular diseases	Acute myocardial infarction, cardiac dysrhythmia, ischemic heart disease, heart failure, stroke/transient ischemic attack
Other cardiovascular diseases	Hypertension, hyperlipidemia (dyslipidemia/lipid disorder), obesity, overweight, type 1 diabetes mellitus, type 2 diabetes mellitus, abnormal glucose, peripheral vascular disease
Renal conditions	Chronic kidney disease, end-stage renal disease
Liver conditions	Cirrhosis and other liver conditions, Hepatitis B, Hepatitis C, NAFLD or NASH
Cancer	<i>Non-AIDS</i> : Breast, lung, colorectal, uterine, liver, Hodgkin's lymphoma, leukemia, prostate, endometrial <i>AIDS-defining cancer</i> : Kaposi sarcoma, non-Hodgkin's lymphoma, cervical <i>HPV-associated cancers</i> : Cervical, vaginal/vulva, anal, oral
Neuropsychiatric conditions	Depression, anxiety disorders, suicidal ideation, bipolar/manic depression, insomnia and sleep-related disorders, amnesic disorder, dementia-type disorders, dissociative and conversion disorder, intellectual disorders, pervasive developmental disorder, psychosis, schizophrenia
Mental health and pain conditions	Dementia/Alzheimer's disease, fatigue, trauma-stressor-related disorders, migraine and chronic headache, substance abuse disorders (opioid use disorders, drug use disorders, alcohol use disorders, tobacco use)
Lung diseases	Chronic obstructive pulmonary disease, asthma
Auto-immune conditions	Rheumatoid arthritis/osteoarthritis, psoriatic arthritis, psoriasis, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease
Endocrine disorders	Hip/pelvic fractures, osteoporosis, hypothyroidism
Gastrointestinal disorders	Diarrhea, nausea/vomiting, peptic ulcer disease, esophageal reflux

Supplemental Table 2: Cancer burden among people living with HIV and people without HIV

Variable	People living without HIV (N = 52,156)	People living with HIV (N = 26,078)	P value
Cancer, non-AIDS defining, n(%)	2,643 (5.7)	1,692 (6.5)	<0.001
Breast	393 (0.7)	201 (0.8)	0.793
Lung	309 (0.6)	150 (0.6)	0.766
Colorectal	325 (0.6)	329 (1.3)	<0.001
Uterine	36 (< 0.1) ^a	18 (< 0.1) ^a	>0.999
Liver	202 (0.4)	62 (0.2)	<0.001
Leukemia or Lymphoma	365 (0.7)	343 (1.3)	<0.001
Prostate	1,238 (2.4)	696 (2.7)	0.012
Endometrial	43 (0.1)	23 (0.1)	0.794
Cancer, AIDS-defining, n (%)	159 (0.30)	314 (1.20)	<0.001
Cervical	<11 (< 0.1) ^a	14 (< 0.1) ^a	0.016
Kaposi's sarcoma	<11 (< 0.1) ^a	> 90 (> 0.3) ^a	<0.001
Non-Hodgkin's lymphoma	148 (0.3)	213 (0.8)	<0.001
Human Papilloma Virus-associated cancer, n (%)	85 (0.2)	253 (0.9)	<0.001
Vaginal/vulva	< 11 (< 0.1) ^a	< 11(0.1) ^a	<0.001
Anal	<11 (< 0.1) ^a	162 (0.62)	<0.001
Oral cavity/pharynx	72 (0.1)	79 (0.3)	<0.001

^a Due to rounding, values lower than 0.05% are presented as < 0.1% and percentages may not total 100%. There were small number of individuals (n<11) for certain cancer type. Therefore, data was coarsened for other categories to preserve confidentiality.